WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Investment

Stryker puts $400M into CMR Surgical and takes an option to buy it

MedDevice Startups Staff · Oct 12 · 2 min read · Via MDDI

Stryker made a roughly $400 million equity investment in CMR Surgical, the companies said October 12. The deal carries an exclusive option for Stryker to acquire 100 percent of CMR's equity, subject to regulatory approvals and closing conditions.

Stryker becomes the exclusive US sales agent for the Versius portfolio. CMR keeps leading development and commercialization everywhere else. Andy Pierce, Stryker's group president for medsurg and neurotechnology, is expected to join the CMR board.

CMR's second-generation Versius Plus cleared FDA late last year. The company says Versius has been used in more than 30,000 surgeries, mostly outside the US. Needham analyst Mike Matson puts the soft tissue robotics market above $12 billion.

The structure buys Stryker a US channel and a look at the numbers before it commits, which is how a strategic hedges against a robot that sells well abroad and stalls in American hospitals.

Questions & Answers

How much did Stryker invest in CMR Surgical?

Stryker invested about $400 million in CMR Surgical, announced October 12, 2026, in exchange for equity plus an exclusive option to acquire 100 percent of the company.

Who will sell the CMR Surgical Versius robot in the United States?

Under the October 2026 agreement, Stryker becomes the exclusive US sales agent for CMR Surgical's Versius portfolio. CMR Surgical continues to lead development and commercialization outside the US.

Does CMR Surgical have FDA clearance for Versius Plus?

Yes. CMR Surgical's second-generation Versius Plus soft tissue surgical robot received FDA clearance in late 2025. CMR says the Versius platform has been used in more than 30,000 surgeries, mostly outside the US.

← Back to M&A